Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines.

ABSTRACT:

Abstract

Homologous recombination deficiency (HRD) drives genomic instability in multiple cancer types and renders tumors vulnerable to certain DNA-damaging agents such as PARP inhibitors. Thus, HRD is emerging as an attractive biomarker in oncology. A variety of in silico methods are available for predicting HRD; however, few of these methods have been applied to cell lines in a comprehensive manner. Here, we utilized two of these methods, “Classifier of HOmologous Recombination Deficiency” and “HRDsum” scores, to predict HRD for 1,332 cancer cell lines and 84 noncancerous cell lines. Cell lines with biallelic mutations in BRCA1 or BRCA2, which encode key components of the homologous recombination pathway, showed the strongest HRD predictions, validating the two methods in cell li

SUBMITTER: Dodson AE 

PROVIDER: S-EPMC11621922 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature